Neptunus Interlong (8329) Announces Renewal of Continuing Connected Sales Framework Agreement

Bulletin Express11-24

Shenzhen Neptunus Interlong Bio-technique Company Limited (stock code: 8329) announced that it entered into a new sales framework agreement with Shenzhen Neptunus Group Company Limited, effective from 1 January 2026 to 31 December 2028. This agreement renews a prior arrangement set to expire on 31 December 2025, enabling continued sales of the company’s self-manufactured or distributed pharmaceutical and related products to Neptunus Group.

According to the announcement, historical sales to Neptunus Group were reported as approximately RMB41.60 million in 2023, RMB43.23 million in 2024, and RMB33.40 million for the first nine months of 2025. The proposed annual caps under the new agreement are RMB56.00 million for 2026, RMB62.00 million for 2027, and RMB69.00 million for 2028. Pricing will remain on terms no more favorable than those offered to independent parties, with settlement generally required within 60 days. The company stated that this arrangement aims to expand product sales and revenues. The new framework will be put to a vote at an extraordinary general meeting scheduled for 23 December 2025.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1155070244?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-24 16:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1155070244","market":"hk","top_or_hot":-1,"title":"Neptunus Interlong (8329) Announces Renewal of Continuing Connected Sales Framework Agreement","media":"Bulletin Express","content":"<p>Shenzhen Neptunus Interlong Bio-technique Company Limited (stock code: 8329) announced that it entered into a new sales framework agreement with Shenzhen Neptunus Group Company Limited, effective from 1 January 2026 to 31 December 2028. This agreement renews a prior arrangement set to expire on 31 December 2025, enabling continued sales of the company’s self-manufactured or distributed pharmaceutical and related products to Neptunus Group.</p>\n<p>According to the announcement, historical sales to Neptunus Group were reported as approximately RMB41.60 million in 2023, RMB43.23 million in 2024, and RMB33.40 million for the first nine months of 2025. The proposed annual caps under the new agreement are RMB56.00 million for 2026, RMB62.00 million for 2027, and RMB69.00 million for 2028. Pricing will remain on terms no more favorable than those offered to independent parties, with settlement generally required within 60 days. The company stated that this arrangement aims to expand product sales and revenues. The new framework will be put to a vote at an extraordinary general meeting scheduled for 23 December 2025.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Neptunus Interlong (8329) Announces Renewal of Continuing Connected Sales Framework Agreement</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNeptunus Interlong (8329) Announces Renewal of Continuing Connected Sales Framework Agreement\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2025-11-24 16:42</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shenzhen Neptunus Interlong Bio-technique Company Limited (stock code: 8329) announced that it entered into a new sales framework agreement with Shenzhen Neptunus Group Company Limited, effective from 1 January 2026 to 31 December 2028. This agreement renews a prior arrangement set to expire on 31 December 2025, enabling continued sales of the company’s self-manufactured or distributed pharmaceutical and related products to Neptunus Group.</p>\n<p>According to the announcement, historical sales to Neptunus Group were reported as approximately RMB41.60 million in 2023, RMB43.23 million in 2024, and RMB33.40 million for the first nine months of 2025. The proposed annual caps under the new agreement are RMB56.00 million for 2026, RMB62.00 million for 2027, and RMB69.00 million for 2028. Pricing will remain on terms no more favorable than those offered to independent parties, with settlement generally required within 60 days. The company stated that this arrangement aims to expand product sales and revenues. The new framework will be put to a vote at an extraordinary general meeting scheduled for 23 December 2025.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"08329","symbol_name":"海王英特龙","start_time":0,"source_url":"","article_id":"1155070244","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1155070244","pubTimestamp":1763973742,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Shenzhen Neptunus Interlong Bio-technique Company Limited (stock code: 8329) announced that it entered into a new sales framework agreement with Shenzhen Neptunus Group Company Limited, effective...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"08329":"海王英特龙"},"translate_title":"海王英特隆(8329)公布续期持续关连销售框架协议","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"08329":1},"content_text":"Shenzhen Neptunus Interlong Bio-technique Company Limited (stock code: 8329) announced that it entered into a new sales framework agreement with Shenzhen Neptunus Group Company Limited, effective from 1 January 2026 to 31 December 2028. This agreement renews a prior arrangement set to expire on 31 December 2025, enabling continued sales of the company’s self-manufactured or distributed pharmaceutical and related products to Neptunus Group.\nAccording to the announcement, historical sales to Neptunus Group were reported as approximately RMB41.60 million in 2023, RMB43.23 million in 2024, and RMB33.40 million for the first nine months of 2025. The proposed annual caps under the new agreement are RMB56.00 million for 2026, RMB62.00 million for 2027, and RMB69.00 million for 2028. Pricing will remain on terms no more favorable than those offered to independent parties, with settlement generally required within 60 days. The company stated that this arrangement aims to expand product sales and revenues. The new framework will be put to a vote at an extraordinary general meeting scheduled for 23 December 2025.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.13","shortVersion":"4.35.13","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1155070244","isCrawlerRequest":true}